4.6 Editorial Material

The Need for Translational Research on Drug-Drug Interactions

Journal

CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 91, Issue 5, Pages 771-773

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.39

Keywords

-

Funding

  1. NCRR NIH HHS [KL2RR024132, KL2 RR024132] Funding Source: Medline
  2. NIA NIH HHS [R01AG025152, R01 AG025152, RC1AG035751, RC1 AG035751] Funding Source: Medline
  3. NICHD NIH HHS [T32-HD069047, U54HD071598, U10HD063094, T32 HD069047, U54 HD071598, U10 HD063094] Funding Source: Medline
  4. NIDDK NIH HHS [R01 DK102694] Funding Source: Medline
  5. NIGMS NIH HHS [T32-GM08425, T32 GM008425] Funding Source: Medline

Ask authors/readers for more resources

Drug-drug interactions (DDIs) are an important clinical and public health concern. Although DDI screening now occurs during drug development, it is difficult to predict clinical importance based on in vitro experiments. Furthermore, older drugs that were not screened may have interactions that have not yet been identified. In this Commentary, we review the importance of DDIs and argue that a translational research approach is needed to produce clinically actionable information as well as generalizable biological knowledge.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available